Targeted endogenous knockin of Wiskott-Aldrich syndrome (WAS) transgene in WAS-iPSCs
Mutant WAS-iPSCs exhibited defective NK- and T-lymphoid cell development and function
Correction of WAS-iPSCs restored lymphoid cell development and function
These results suggest the potential therapeutic use of gene-corrected WAS-iPSCs